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ABSTRACT 
OBJECTIVE: To characterize the availability of tracer medicines in pharmaceutical services in 
primary health care of the Brazilian Unified Health System (SUS). 
METHODS: This is a cross-sectional and evaluative study, part of the Pesquisa Nacional Sobre Acesso, 
Utilização e Promoção do Uso Racional de Medicamentos – Serviços, 2015 (PNAUM – National Survey on 
Access, Use and Promotion of Rational Use of Medicines – Services, 2015). To analyze the availability 
of medicines, we verified 50 items selected from the Relação Nacional de Medicamentos Essenciais 
(Rename – National List of Essential Medicines) of  2012. Observation scripts were applied to medicine 
dispensing services in the primary health care. Interviews were carried out with patients, health care 
professionals, and public managers, using semi-structured questionnaires. The availability index 
was presented as the percentage of health units where the medicines were available. For statistical 
analysis, absolute, relative, and mean frequencies were presented (with 95% confidence intervals). The 
comparison of groups was carried out by Pearson Chi-square tests or variance analysis, when needed. 
RESULTS: One thousand, one hundred, and seventy-five observation scripts were filled in a 
national representative sample composed by 273 cities. Statistically significant differences 
were observed regarding the type of unit, infrastructure, and presence of a pharmacist between 
regions of Brazil. The average availability of tracer medicines in primary health care was 52.9%, 
with differences between regions and sampling strata. This index increased to 62.5% when 
phytotherapic medicines were excluded. We found limited availability of medicines for treatment 
of chronic and epidemiological diseases, such as tuberculosis and congenital syphilis. 
CONCLUSIONS: The low availability of essential medicines purchased centrally by the Brazilian 
Ministry of Health indicates deficiencies in supply chain management. The different views on the 
availability of tracer medicines in SUS confirm the general availability verified in this study. Among 
patients, about 60% said they obtain medicines in SUS units, data consistent with the lack of medicines 
reported by medicine dispensers and in line with physicians’ evaluations.
DESCRIPTORS: Drugs, Essential, supply & distribution. Pharmaceutical Services. Primary 
Health Care. Health Services Research. Unified Health System.
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INTRODUCTION
Primary health care is characterized by individual and collective actions, comprising 
health promotion and protection, injury prevention, diagnosis, treatment, rehabilitation, 
and health maintenance. High-complexity and low-density technologies are used 
to solve relevant problems in the health services’ territory. Medicines are one of the 
most important technologies used by modern society and a fundamental health care 
therapeutic resource21,23. 
Important changes in the epidemiological profile that occurred in the last century led to a 
significant increase in life expectancy and  increase in life expectancy and predominance 
of predominance of chronic non-communicable diseases (CNCD)3,12. Currently, health care 
in Brazil is characterized by an accelerated demographic transition and expressed by triple 
burden of disease: an agenda of infectious diseases not yet overcome, diseases associated 
with external causes, and the chronic conditions’ hegemony. The answer to this situation has 
been structured by the health care network, with access to actions and services coordinated 
by primary health care8,12. 
In this context, pharmaceutical services play an essential role. One of the nine global goals for 
CNCD control is to ensure 80% of availability of essential medicines and basic technologies, 
since the appropriate pharmacological treatment significantly reduces morbidity and 
mortality of these diseases. Appropriate availability, associated with sustainable funding 
and improvement of the health care system, contribute to ensure a universal coverage3,7,24,25. 
Pharmaceutical services in primary health care aim to ensure a comprehensive, continuous, 
and compatible health care for the population, with medicines being one of the essential 
elements21. As part of the constitutional right to health, the pharmaceutical services in 
the Brazilian Unified Health System (SUS)a comprise administrative activities to ensure 
an adequate availability of medicines, their quality and conservation, besides assistance 
services, focusing on therapeutic effectiveness and safety21.
Ensuring that the population has access to essential medicines is one of the eight Millennium 
Development Goals26 and, therefore, one pillar of the national health care policies formulation 
and implementation20. Despite being a fundamental factor of the right to health, the access 
to essential medicines to prevent and treat high prevalence disorders, including chronic 
respiratory and cardiovascular diseases and diabetes, it may still be considered low and 
irregular worldwide2,8,21.
The concept of access is wide and comprises five dimensions – availability, accessibility, 
accommodation, acceptability, and affordability10,22. Availability is an important 
and challenging aspect, especially in publicly funded universal health systems. It is 
defined as the relationship between the type and quantity of products required and 
those offered11,20. Under the perspective of public and universal health care systems, 
the analysis of availability is often taken as a proxy for the evaluation of the access to 
essential medicines.
Studies carried out at Brazilian primary health care units point out issues on the availability 
and quality of drugs use and deficiencies in logistics and supply chain management, 
despite the legal framework of pharmaceutical servicesa and growing investments made 
by the three levels of SUS management3,9,13,20. The Pesquisa Nacional sobre Acesso, Utilização 
e Promoção do Uso Racional de Medicamentos – Serviços (PNAUM – National Survey on 
Access, Use and Promotion of Rational Use of Medicines – Services) aimed to characterize 
pharmaceutical services in SUS primary health care – for promoting the access and rational 
use of medicines –, as well as to identify and discuss the factors that affect the consolidation 
of pharmaceutical services in the municipalities. 
This study aimed at identifying factors related to the availability of tracer medicines in 
pharmaceutical services of SUS primary health care. 
a The national policies of 
medicines and pharmaceutical 
services establish the guidelines 
for pharmaceutical services in 
Brazil15,16.
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METHODS
This study is part of PNAUM – Services, a cross-sectional, exploratory, and evaluative survey, 
with a representative sample of cities, primary health care services, patients, physicians, and 
medicine dispensers in the five regions of Brazil. The sampling plan considered the different 
populations under study and estimated different sampling sizes for each population1. In each 
region, 120 cities, 300 health care services, and 1,800 users were sampled. The total sample 
(600 cities) was stratified in capitals (26 and the Federal District); biggest cities (the 0.5% 
biggest cities in the region, totaling 27), and smallest cities in population (546 cities chosen 
by lot). For obtaining the health care services’ sample, sixty cities by region were chosen by lot 
among the 120 previously selected. Primary health care units, health care centers, or basic/
mixed health units were included in the draw of health services, according to the Cadastro 
Nacional de Estabelecimentos de Saúde (CNES – National Register of Health Establishments). 
Face-to-face interviews were held with patients, physicians, and medicine dispensers in 
primary health care services, as well as telephone interviews with those responsible for 
pharmaceutical services in the cities, using a structured questionnaire specific for each 
category. Respondents were asked about availability of medicines in the three-month period 
before the interview. Pharmaceutical services’ facilities and availability of medicines were 
assessed using an observation script. A handbook and a glossary of technical terms were 
elaborated for each survey instrument. After training the interviewers, a pretest was carried 
out, involving cities with different population size to improve and validate the instruments. 
The data were collected between July 2014 and May 2015.
Availability was assessed using a list of tracer medicines. A group of experts has selected 58 
medicines from the Relação Nacional de Medicamentos Essenciais (Rename – National List of 
Essential Medicines) of 2012, grouped according to their therapeutic class in 50 assessment 
items. The guiding criterion for choosing them were the parameters established by the World 
Health Organization (WHO)25 to enable researches on availability of essential medicinesb, 
including those indicated for the treatment of epidemiological relevant conditions in the 
Country within primary health care. 
Availability was defined as the presence of at least one pharmaceutical unit of the medicine, 
visible at the time of data collection, according to direct observation of the field researcher. 
For medicines in the same therapeutic category, grouped in one item, we considered the 
availability of at least one unit among therapeutic options established. The availability 
index was presented as the percentage of health units evaluated where the medicines were 
available. For statistical analysis, absolute, relative, and mean frequencies were presented 
(with 95%CI for relative and mean frequencies). The comparison of groups was made using 
Pearson Chi-square tests or variance analysis, when needed. 
Data analysis was performed using the software SPSS® version 22, using the plan of complex 
samples1. The research was approved by the National Research Ethics Committee, under 
CONEP opinion no. 398.131/2013. All interviews were preceded by explanation of the research 
objectives to the respondent and by the signing of the informed consent form.
RESULTS
In total, 1,175 observation scripts were filled in 273 Brazilian cities. For organizational issues 
of pharmaceutical services, some of the cities centralize the dispensing of medicines in 
public pharmacies located in independent buildings or in bigger health centers. Statistically 
significant differences were observed between Brazilian regions, regarding type of unit, 
infrastructure, and existence of pharmacist in units that supply medicines where the 
observation script were applied (Table 1).
The average availability of tracer medicines in SUS primary health care was 52.9%, with 
statistically significant differences between regions (p<0.05). We observed relevant 
b To make a research on 
the availability of essential 
medicines in health services 
feasible, the WHO suggests 
choosing a maximum of 50 items 
from a list of essential medicines. 
This list of key medicines, 
called tracer medicines, 
must contain items destined 
to treatment of main health 
conditions of the population, 
including a standard list of 14 
medicines, to allow international 
comparisons, a regional basic 
list of up to 16 medicines, and a 
complementary list of at least 20 
medicines of national relevance 
(WHO25, 2008).
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amplitude between the evaluated items (Table 2). Oral re-hydration salts presented 
the highest availability (91.9%) and phytotherapic medicines, the lowest (ranging from 
0.8% to 8.6%). When we analyzed all medicines, except phytotherapic ones, the average 
increased to 62.5%. 
The availability index ranged according to the population stratum (capitals, biggest cities 
of each region and smallest cities), and the lowest availability was registered in the smallest 
cities (Figure 1). This variation occurred independently of the exclusion of phytotherapic 
medicines, with statistical significance (p<0.05).
Availability in the past three months was assessed from the perspective of patients, 
physicians, and medicine dispensers (Table 3). According to 58.8% of physicians, the 
availability of essential medicines was considered very good/good. When there is lack of 
medicines, the most frequent action is analyzing the possibility of replacing the medicine 
prescribed for therapeutic alternatives (77.4%), followed by referral to the Popular 
Pharmacy Program (75.4%).
Among the medicine dispensers, 38.0% reported lack of medicines takes place always 
or repeatedly in SUS primary health care units. According to those responsible for 
pharmaceutical services in the cities, insufficient financial resources (31.4%), problems 
in the pharmaceutical market (30.5%), delay in the transfer of medicines by other 
management instances of the SUS (27.2%), and disorganization of the local acquisition 
sector (18.8%) were the main reasons for shortages in the year before the survey (data 
not presented in table).
Among patients, 67.0% reported they always or repeatedly obtained the medicines they 
needed in SUS primary health care pharmacies. When the prescribed medicines were not 
provided, patients almost always did not receive further instructions from the dispensing 
unit (75.6%). In 10.9% of the cases, the lack of medicines was reported.
Table 1. Description of medicine dispensing units in SUS primary health care. National Survey on Access, Use and Promotion of Rational 
Use of Medicines – Services, 2015.
Variable
North Northeast Midwest Southeast South Brazil
na % (IC95%) na % (IC95%) na % (IC95%) na % (IC95%) na % (IC95%) na % (IC95%)
Type of unitb
Center/basic health unit 179 68.8 (62.3–74.6) 181 72.9 (63.9–80.3) 53 25.4 (16.2–37.5) 124 42.0 (29.7–55.5) 171 64.5 (52.1–75.1) 708 58.8 (53–64.3)
Health Center 24 8.7 (5.7–13.1) 56 13.9 (9.8–19.4) 88 28.4 (18.7–40.6) 49 15.4 (10.4–22.4) 40 12.4 (7.6–19.7) 257 14.6 (12–17.6)
Pharmacy in an 
independent building 
37 15.5 (11.2–20.9) 6 4.1 (1.0–15.3) 20 37.4 (20.2–58.5) 22 17.8 (10.4–28.8) 31 16.8 (7.9–32.4) 116 13.4 (9.6–18.3)
Mixed unit 8 3.3 (1.6–6.5) 11 4.3 (1.7–10.5) 16 7.5 (3.1–16.8) 31 20.3 (9.9–37.3) 7 5.7 (1.9–15.7) 73 9.6 (5.7–15.8)
Other 11 3.8 (2.0–7.1) 5 4.8 (1.6–13.5) 1 1.3 (0.2–9.0) 3 4.4 (0.8–20.5) 1 0.6 (0.1–4.0) 21 3.7 (1.6–8.2)
Unit has a responsible 
pharmacistb
78 26.8 (21.9–32.2) 52 18.5 (11.7–28.1) 95 66.9 (55.6–76.6) 176 72.0 (57.3–83.1) 105 44.8 (34.5–55.6) 506 43.0 (37.8–48.4)
Equipment and furnishings of the storage areab
Exclusive refrigerator for 
medicines
97 37.2 (31.0–43.8) 97 21.3 (16.1–27.6) 112 50.7 (36.6–64.7) 180 76.0 (65.9–83.9) 164 56.8 (46.7–66.4) 650 47.2 (42.0–52.5)
Air conditioner 163 59.0 (52.4–65.4) 92 21.3 (14.8–29.5) 103 72.7 (61.6–81.6) 101 46.0 (33.1–59.4) 76 37.1 (26.7–48.8) 535 37.7 (32.4–43.2)
Locker cabinetc 99 38.2 (32.0–44.7) 66 22.6 (15.9–31.1) 80 65.1 (50.7–77.3) 154 63.4 (49.6–75.3) 103 48.9 (38.5–59.5) 502 43.4 (38.0–49.0)
a Non-weighted n value
b p-value < 0.05
c For storage of medicines subject to special control, such as antipsychotics, anxiolytics, and sedatives, regulated by Ordinance GM/MS no. 344/98.
Source: PNAUM – Services, 2015.
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Table 2. Average availability of essential medicines in the visited primary health care dispensing units. National Survey on Access, Use and 
Promotion of Rational Use of Medicines – Services, 2015.
Medicine
Availability % (95%CI)
North Northeast Midwest Southeast South Brazil
Anti-hypertensives 73.5 (68.9–78.2) 85.9 (82.2–89.6) 86.1 (80.5–91.6) 91.8 (88.5–95.1) 84.0 (78.7–89.4) 84.3 (82.2–86.3)
1. Captopril/enalaprila 84.1 (78.5–88.4) 84.4 (78.3–89.0) 84.1 (75.9–89.9) 95.4 (91.2–97.6) 83.9 (76.7–89.3) 87.7 (84.8–90.1)
2. Hydrochlorothiazide 72.9 (66.5–78.5) 86.6 (80.1–91.2) 81.7 (73.2–88.0) 86.1 (79.6–90.8) 83.5 (76.1–89.0) 84.5 (81.3–87.3)
3. Atenolol/propranolol/carvedilol/
metoprolola
70.7 (64.2–76.4) 66.2 (58.4–73.1) 77.6 (65.1–86.6) 90.9 (85.0–94.7) 79.2 (69.8–86.2) 77.1 (73.1–80.6)
Oral antidiabetics and insulin 66.4 (61.7–71.1) 77.1 (72.9–81.3) 80.5 (72.6–88.4) 91.1 (87.7–94.4) 74.9 (69.0–80.8) 78.0 (75.6–80.4)
4. Metformina 79.2 (73.4–84.0) 86.4 (80.0–90.9) 83.8 (74.8–90.1) 91.8 (84.9–95.7) 74.0 (61.4–83.5) 85.2 (81.4–88.4)
5. Glibenclamide/glicazide 79.2 (73.1–84.2) 85.3 (76.8–91.1) 84.3 (74.3–90.9) 84.6 (76.9–90.0) 72.9 (64.3–80.1) 82.4 (78.5–85.8)
6. NPH human insulina 49.5 (42.9–56.0) 55.5 (47.3–63.4) 65.6 (53.0–76.4) 90.3 (84.5–94.1) 67.8 (57.9–76.3) 68.4 (64.0–72.6)
7. Regular human insulina 45.2 (38.7–51.8) 50.6 (42.4–58.8) 64.9 (52.2–75.9) 84.6 (77.3–89.9) 59.8 (49.8–69.0) 63.1 (58.2–67.7)
Contraceptives/hormones 56.3 (51.2–61.4) 69.5 (63.2–75.7) 81.8 (76.0–87.5) 88.3 (83.8–92.9) 83.1 (78.7–87.5) 75.8 (73.5–78.1)
8. Ethinylestradiol + levonorgestrela 48.6 (42.3–54.9) 63.1 (54.6–70.8) 84.1 (75.6–90.1) 87.0 (80.0–91.8) 86.6 (79.1–91.7) 74.5 (70.1–78.4)
9. Norethindrone + estradiola 53.1 (46.6–59.4) 64.1 (55.7–71.8) 78.6 (66.4–87.2) 82.7 (74.7–88.6) 87.6 (80.8–92.2) 73.8 (69.3–77.8)
10. Norethisteronea 52.0 (45.6–58.4) 65.5 (57.1–73.1) 72.9 (61.6–81.8) 73.8 (58.8–84.8) 82.3 (75.3–87.6) 70.2 (64.7–75.2)
11. Medroxyprogesteronea 44.9 (38.7–51.4) 45.1 (37.1–53.3) 61.7 (50.1–72.1) 71.6 (61.1–80.3) 72.1 (63.3–79.5) 58.8 (53.6–63.8)
12. Levonorgestrel 46.3 (40.1–52.7) 54.1 (45.7–62.3) 66.5 (56.3–75.4) 62.5 (46.7–76.1) 62.1 (52.3–70.9) 58.2 (52.2–63.8)
13. Estriol vaginal creama 15.4 (11.5–20.3) 20.0 (14.8–26.4) 38.7 (28.3–50.3) 15.4 (10.9–21.3) 27.9 (20.0–37.4) 20.6 (17.5–24.2)
14. Conjugated Estrogens Vaginal cream 10.2 (7.0–14.4) 17.7 (12.4–24.7) 31.0 (20.0–44.7) 18.3 (12.4–26.2) 20.8 (14.5–28.9) 18.6 (15.3–22.4)
Anti-infectious 62.7 (58.2–67.2) 70.0 (65.4–74.7) 76.7 (70.5–82.8) 83.9 (80.1–87.8) 73.3 (66.7–79.9) 73.3 (70.9–75.7)
15. Fluconazole/itraconazola 69.2 (62.6–75.0) 67.2 (59.3–74.3) 83.2 (76.8–88.0) 88.5 (82.1–92.8) 67.3 (57.8–75.6) 74.9 (70.8–78.7)
16. Miconazole nitratea 62.7 (56.0–68.9) 64.1 (56.1–71.4) 72.4 (63.1–80.1) 83.0 (74.9–88.9) 84.4 (75.2–90.6) 73.7 (69.4–77.6)
17. Ciprofloxacin chloridea 51.4 (44.8–57.8) 59.7 (51.6–67.3) 60.7 (49.4–70.9) 82.7 (74.5–88.7) 54.0 (43.8–63.9) 65.3 (60.5–69.7)
18. Nystatin creama 44.0 (37.6–50.6) 54.7 (46.6–62.6) 60.1 (44.2–74.0) 68.0 (57.0–77.3) 53.1 (42.4–63.5) 58.0 (52.7–63.1)
19. Benzathine benzylpenicilina 59.0 (52.5–65.3) 37.2 (29.7–45.4) 49.0 (37.4–60.8) 56.3 (42.0–69.7) 60.7 (50.9–69.7) 49.5 (44.0–55.0)
Analgesics/antipyretics/
anti-inflammatory 
73.9 (69.2–78.6) 80.6 (75.8–85.5) 85.9 (78.8–93.0) 91.0 (86.3–95.7) 95.3 (92.5–98.0) 85.3 (83.1–87.6)
20. Paracetamola 84.8 (79.4–89.1) 83.4 (77.2–88.2) 87.2 (77.6–93.1) 95.4 (90.5–97.8) 98.9 (95.9–99.7) 90.1 (87.3–92.3)
21. Dipyrone oral solution 86.0 (80.6–90.1) 83.0 (76.9–87.7) 83.3 (73.0–90.2) 86.2 (74.4–93.1) 93.5 (87.3–96.7) 86.0 (82.0–89.3)
22. Ibuprofena 58.8 (52.2–65.1) 57.4 (49.1–65.4) 83.4 (73.7–90.0) 75.3 (58.8–86.8) 94.3 (89.7–96.9) 70.8 (65.1–75.9)
Antiemetics/antisecretory 54.3 (49.5–59.1) 65.3 (59.6–71.0) 76.5 (68.3–84.7) 80.3 (73.1–87.5) 83.2 (75.9–90.4) 71.9 (68.9–74.9)
23. Omeprazola 32.0 (26.3–38.4) 55.1 (46.7–63.1) 54.6 (41.6–66.9) 82.8 (73.8–89.1) 85.9 (76.7–91.9) 66.9 (62.1–71.4)
24. Aluminium hydroxidea 64.7 (58.5–70.5) 64.4 (56.0–72.0) 77.5 (69.7–83.8) 44.4 (32.4–57.1) 68.4 (55.7–78.8) 59.7 (53.7–65.5)
25. Ranitidine hydrochloride 59.6 (52.8–66.0) 50.2 (42.0–58.4) 70.0 (59.4–78.8) 61.3 (46.9–74.0) 59.7 (48.1–70.2) 57.1 (51.4–62.7)
Anti-asthmatics 67.4 (62.3–72.5) 78.2 (73.0–83.5) 82.1 (76.0–88.1) 88.8 (84.4–93.2) 83.6 (78.7–88.5) 80.0 (77.7–82.3)
26. Prednisolone sodium phosphate/
prednisolonea
64.9 (58.3–71.0) 74.6 (65.7–81.7) 83.6 (76.8–88.7) 86.6 (75.6–93.1) 80.5 (66.1–89.9) 79.0 (74.0–83.3)
27. Salbutamol sulphatea 61.6 (55.0–67.8) 59.3 (50.9–67.2) 69.2 (55.9–79.9) 81.3 (70.6–88.7) 64.2 (54.8–72.6) 67.7 (62.7–72.3)
28. Ipratropium bromide 57.3 (50.6–63.7) 57.9 (49.8–65.7) 62.1 (50.5–72.5) 60.5 (46.4–73.0) 70.8 (60.9–79.1) 61.1 (55.5–66.4)
Antiparasitic agents 70.3 (65.5–75.1) 84.2 (77.9–90.5) 83.1 (76.5–89.7) 91.2 (87.5–94.8) 85.7 (80.1–91.3) 82.9 (80.4–85.4)
29. Albendazola 87.9 (83.0–91.6) 81.4 (72.4–87.9) 80.7 (67.8–89.2) 92.3 (87.3–95.4) 95.9 (92.4–97.8) 87.7 (83.8–90.7)
30. Metronidazole/teclozana 74.0 (68.1–79.1) 82.4 (73.8–88.6) 77.4 (64.2–86.8) 89.3 (83.4–93.3) 78.1 (69.8–84.7) 82.9 (78.9–86.2)
31. Permethrina 15.5 (11.6–20.4) 46.6 (38.7–54.7) 55.7 (46.1–64.9) 57.5 (43.7–70.2) 80.0 (71.9–86.1) 53.6 (48.1–59.0)
Continue
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Table 2. Average availability of essential medicines in the visited primary health care dispensing units. National Survey on Access, Use 
and Promotion of Rational Use of Medicines – Services, 2015. Continuation
Psychotropics 15.0 (11.0–19.0) 10.6 (4.4–16.9) 41.6 (30.2–53.0) 48.0 (35.0–61.1) 45.7 (35.0–56.4) 32.2 (27.9–36.5)
32. Amitriptyline hydrochloridea 17.7 (13.5–22.8) 10.8 (5.9–19.0) 38.4 (27.1–51.1) 49.3 (36.3–62.5) 50.4 (40.2–60.6) 31.5 (26.4–37.1)
33. Carbamazepinea 17.4 (13.3–22.5) 12.5 (7.0–21.3) 42.1 (29.9–55.2) 46.0 (33.2–59.4) 47.3 (36.8–580.) 30.8 (25.6–36.6)
34. Fluoxetinea 11.2 (8.0–15.4) 8.6 (4.1–17.3) 34.8 (22.2–49.9) 50.3 (37.1–63.4) 48.3 (37.9–58.8) 29.9 (24.8–35.6)
35. Clonazepama 17.9 (13.8–22.9) 8.8 (4.3–17.1) 36.2 (24.2–50.2) 46.1 (33.3–59.4) 34.0 (23.2–46.8) 26.9 (21.9–32.6)
Tuberculostatics 32.5 (27.7–38.2) 10.6 (5.9–15.4) 32.2 (21.3–43.2) 44.7 (31.3–58.1) 9.9 (6.4–13.3) 26.0 (22.2–29.8)
36. Isoniazid 75 mg + rifampicin 
150 mg + pyrazinamide 400 mg + 
ethambutol 275 mga
35.6 (29.7–42.0) 10.2 (6.4–15.9) 31.8 (22.0–43.5) 40.7 (29.3–53.3) 9.4 (6.4–13.4) 22.9 (19.1–27.1)
37. Rifampicin 300 mga 30.4 (24.8–36.7) 9.4 (5.6–15.4) 27.8 (18.1–40.1) 36.7 (24.2–51.4) 7.1 (4.7–10.6) 20.3 (15.6–26.0)
Phytotherapics 9.8 (7.4–12.2) 2.8 (0.7–4.9) 12.4 (0.5–24.3) 13.9 (7.5–20.4) 10.8 (6.0–15.6) 8.8 (6.4–11.0)
38. Guacoa 10.6 (8.4–13.4) 2.7 (1.2–5.8) 12.0 (4.2–29.7) 12.7 (8.4–18.9) 11.5 (7.2–17.8) 8.5 (6.6–10.7)
39. Soy isoflavonea 1.5 (0.8–3.0) 0.3 (0.1–1.3) 7.4 (1.2–33.6) 10.0 (6.1–15.9) 3.8 (1.7–8.4) 4.4 (3.0–6.4)
40. Unha-de-gatoa – – – 9.5 (5.8–15.3) – 3.0 (1.9–4.5)
41. Espinheira-santaa 1.2 (0.5–2.6) 0.2 (0.0–1.1) 7.2 (1.2–33.9) 1.8 (0.9–3.6) 2.6 (1.0–6.9) 1.6 (0.8–3.0)
42. Aroeiraa – 0.5 (0.2–1.4) 7.2 (1.2–33.9) 1.2 (0.3–4.2) – 1.0 (0.4–2.6)
43. Cáscara-sagradaa 0.2 (0.0–1.4) 0.2 (0.0–1.1) 0.5 (0.1–3.6) 2.9 (0.7–12.0) – 1.0 (0.3–3.7)
44. Garra-do-diaboa 0.2 (0.0–1.2) – 0.1 (0.0–0.9) 2.0 (1.0–3.8) 1.0 (0.2–3.7) 0.8 (0.5–1.4)
45. Artichoke 2.0 (1.1–3.5) 0.6 (0.3–1.6) – 1.4 (0.6–3.3) – 0.8 (0.5–1.4)
Other medicines 70.6 (65.8–75.5) 81.4 (76.3–86.6) 81.3 (75.3–87.3) 92.3 (88.7–95.8) 79.5 (74.4–84.5) 81.0 (78.8–83.2)
46. Oral rehydration salts 88.0 (83.0–91.7) 89.7 (83.5–93.7) 89.5 (82.1–94.1) 95.8 (90.2–98.3) 92.3 (87.2–95.5) 91.9 (89.1–94.0)
47. Ferrous sulfatea 69.6 (63.3–75.3) 90.4 (85.1–93.9) 84.8 (75.6–91.0) 94.6 (90.2–97.1) 91.5 (82.9–96.0) 89.9 (87.2–92.0)
48. Dexamethasone cream/ointmenta 70.0 (63.6–75.8) 69.1 (61.2–76.1) 82.7 (74.5–88.6) 90.7 (82.4–95.3) 86.0 (76.1–92.2) 79.5 (75.3–83.1)
49. Folic acida 65.5 (58.9–71.6) 72.9 (65.2–79.4) 72.4 (58.3–83.2) 81.0 (70.9–88.1) 87.8 (80.3–92.7) 77.3 (72.9–81.1)
50. Nicotinea 4.5 (2.4–8.1) 4.4 (2.0–9.3) 34.0 (23.0–46.9) 27.2 (17.8–39.3) 17.0 (8.5–31.1) 15.3 (11.6–19.9)
General availability 44.6 (42.8–46.3) 46.3 (44.2–48.4) 55.9 (51.3–60.5) 60.5 (58.3–62.8) 56.8 (54.6–58.9) 52.9 (51.6–54.2)
General availability excluding 
phytotherapicsb
52.7 (50.6–54.8) 55.0 (52.5–57.5) 65.7 (60.9–70.5) 71.1 (68.6–73.6) 67.2 (64.6–69.7) 62.5 (60.9–64.0)
NPH: Neutral Protamine Hagedorn 
a p < 0,05
b Availability measures considered the availability of tracer medicines checked by the observation script, excluding items 38 to 45.
Source: PNAUM – Services, 2015.
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Figure. Average availability of tracer medicines in primary health care units, according to sampling 
stratum. National Survey on Access, Use and Promotion of Rational Use of Medicines – Services, 2015.
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DISCUSSION
The analysis of essential medicines’ availability is an important strategy to assess the impact 
of policies introduced in public health25. In Brazil, the importance of studies on access and 
quality of pharmaceutical services in the SUS is even greater, since there is evidence that 
the public supply is the only way to access medicines for low income families3,10.
This study found an average availability of 52.9%, which was higher than an average availability 
of 44.9% found by Mendes et al.13 for essential medicines in Brazilian primary health care, 
and similar to the average of 40 developing countries found by Cameron et al.7
According to the regulation of the Basic Component of Pharmaceutical Services (CBAF) 
in the SUSc, cities can create a list of medicines that meet local demand, since the items 
are covered by the ruling Rename Appendices. However, as observed by Helfer et al.10, this 
autonomy cannot prevent professionals from meeting the prevalent injuries. One cannot 
affirm that the low general availability has been counterbalanced by the provision of locally 
standardized alternatives3,10,13. A limitation of data analysis presented in this study is the lack 
of access to the respective municipal lists.
General availability varied according to the regions of the Country, being lower in the North and 
Northeast regions (44.6% and 46.3%, respectively). These regions also showed the lowest indexes for 
the following variables: existence of a responsible pharmacist, exclusive refrigerator for medicines, 
and locker cabinets for medicines under special control. These data corroborate Mendes et al.13 
findings, which associated higher availability of medicines in primary health care with adequate 
infrastructure (storage area, air conditioning, and refrigerator) and pharmacist support.
c  Rules for funding and 
implementation of the Basic 
Component of Pharmaceutical 
Assistance within the Brazilian 
Unified Health System are 
regulated by governmental decree 
no. 1,555 from July 30, 201319.
Table 3. Perception of patients, physicians, and medicine dispensers in primary health care services on the availability of medicines. National 
Survey on Access, Use and Promotion of Rational Use of Medicines – Services, 2015.
 Perceived availability na % (IC95%)
Patients
Frequency of acquisition of needed medicines in the past three monthsb
Always 3,357 59.8 (55.1–64.4)
Repeatedly  410 7.1 (4.7–10.7) 
Sometimes 1,313 23.1 (20.0–26.5)
Rarely  421 5.6 (4.6–6.9) 
Never 257 4.3 (3.0–6.1) 
Information received when did not receive the medicine(s)b
Lack in unit 1,043 10.9 (8.7–13.5)
Referred to another unit of the Brazilian Unified Health System 242 1.8 (1.2–2.8)
Received instructions to buy the medicine 623 8.3 (6.7–10.1)
Referred to the Popular Pharmacy Program 278 3.1 (2.4–4.0)
Others 33 0.3 (0.2–0.4)
No instructions 6,584 75.6 (72.5–78.5)
Physicians
Availability of medicines in the past three months
Very good/Good 654 58.8 (54.8–62.7)
Neither bad/Nor good 437 34.3 (30.6–38.2)
Bad/Very bad 95 6.9 (5.1–9.3)
Conduct in situations of lack of medicines in the municipal health systemb
Analyses the possibility of replacing the medicine prescription 1,240 77.4 (74.2–80.4)
Refers to the Popular Pharmacy Program in the city 1,202 75.4 (72.1–78.3)
Recommends the purchase 1,090 69.3 (66.0–72.5)
Refers to Aqui tem Farmácia Popular 1,049 66.8 (63.4–70.1)
Medicine dispensers
Lack of medicines in the past three monthsb
Always 376 27.7 (21.8–34.5)
Repeatedly  117 10.3 (6.2–16.6) 
Sometimes 412 35.6 (29.3–42.5)
Rarely  141 16.3 (11.8–2.1) 
Never 91 10.1 (6.0–16.3)
a Non-weighted n value
b p <0,05
Source: PNAUM – Services, 2015.
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Availability varied according to the population size – capitals and the 0.5% largest cities 
included in the sample presented better availability than other cities. This relationship between 
improved availability and size of population was also identified in Brazil by other studies in 
which medicine supply rates were higher in bigger cities3,13. These findings suggest structural 
and management deficiencies in small cities to properly meet local health demands.
Overall average availability, when excluding phytotherapic medicines, was 62.5%, similar 
to Mendes et al.13 findings (58.5%). Although the national policy and funding provided by 
CBAF19, phytotherapic medicines were available in only 8.8% of the units. The low availability 
of these medicines shows the need for using strategies for rendering effective integrative 
and complementary practices in the Country, to ensure the adoption of innovative and 
socially contributory alternatives. Brazil has many advantages and opportunities for the 
development of this therapy, such as the world’s greatest plant diversity, huge socio-diversity, 
and traditional knowledge6,20. 
Low availability of medicines in the public sector is a global issue, and medicines for chronic 
diseases are even scarcer than those for acute diseases, particularly in low and middle 
income countries7. Medicines are very important in treatment of morbidities that present 
increasing prevalence in Brazil due to population ageing3,12, such as chronic degenerative 
diseases (hypertension and diabetes mellitus) and mental health problems. 
In this study, indexes above the 80% recommended by the WHO3,25 were found for some 
antihypertensive medicines (captopril/enalapril and hydrochlorothiazide) and oral 
antidiabetic medicines (metformin, glyburide/gliclazida), but they were lower for beta-
blockers, insulin, psychotropic medicines, and those for asthma treatment. These findings 
are consistent with some studies developed in the Country3,10,13. 
Among the medicines for CNCD treatment, psychotropics presented the lowest availability. 
Although some studies10,13 suggest a centralized supply of medicines subjected to special 
control in municipal public services, the low availability verified is relevant and represents a 
challenge to health care integrality. Treatment interruption as a result of shortages may result 
in hospitalizations for mental illness, reduce the patients quality of life, and increase health 
care costs. The improvement of access to essential psychotropic drugs is a key component 
to strengthen mental health care. 
Infrastructure problems in SUS dispensing units can also be associated with the low availability 
verified for some items. Only 47.2% of the units had an exclusive refrigerator for storage of 
thermolabile medicines. Even though this index is higher than the 25.0% identified by Mendes et al.13, 
the low availability of NPH and regular human insulin (68.4% and 63.1%, respectively) is also found 
in many national and international studies3,4,13. Insulins are essential medicines to people with 
diabetes and are considered essential medicines the by WHO Global Action Plan26 for the 
prevention and control of CNCD, and should always be available to the population.
Besides insulins, the Brazilian Ministry of Health purchases contraceptives and hormones for 
the Women Health Program, tuberculostatics, and smoking cessation medicines centrally. 
All of them presented availability below 80% in the national average, especially strategic 
medicines (tuberculostatics and nicotine), with availability inferior to 40% in all Country regions. 
Tuberculosis is an important public health problem in Brazil, being the ninth cause of 
hospitalization and the fourth cause of mortality due to infectious diseases18. Ensuring access 
to medicines is an essential component in the reduction of the tuberculosis prevalence in 
the Country and, consequently, in the Americas. Thus, the low availability verified (22.9%) 
in primary health care units presents a challenge for the health system.
Low availability of medicines acquired centrally suggests eventual deficiencies in medicine 
supply chain. This hypothesis is consistent with the perception of professionals responsible 
for pharmaceutical services, who highlighted the delay in the transfer by the management 
instances of SUS as one of the main reasons for medicine shortage in the cities. 
9s
Availability of medicines in the SUS Nascimento RCRM et al.
https://doi.org/10.11606/S1518-8787.2017051007062
Regarding medicines for treatment of acute conditions, it is important to highlight 
the low availability of antiemetics and some anti-infective agents, such as benzathine 
benzylpenicillin. Eliminating congenital syphilis as a public health problem is a priority in 
Latin America and in the Caribbean region. WHO estimates one million cases of syphilis in 
pregnant women per year and preconize early detection and proper treatment of women 
and their partners to prevent serious implications for the baby5. Penicillin is the chosen 
treatment for cases of syphilis, and a continuous provision of this medicine is essential 
in primary health care services.
The different perceptions on availability of tracer medicines in the SUS corroborate the 
indexes of overall availability found in this study. Among patients, approximately 60% 
say they obtain the medicines needed in SUS units, data consistent with the lack of 
medicines reported by medicine dispensers and with the evaluation of primary health 
care physicians. 
When there is lack of medicines, the most frequent actions described by the physicians were 
analyzing the possibility of replacing the medicine prescribed and referring the patient to 
the Popular Pharmacy Program. It is important to highlight that the first strategy is more 
feasible for the treatment of acute conditions. Replacement of continuous-use medicines 
may compromise the control of the disease and/or the adherence to therapy, affecting the 
treatment effectiveness. Regarding the referral to the Popular Pharmacy Program, only nine 
(18%) of the 50 checked items are provided for freed by private pharmacies participating in 
the program Aqui Tem Farmácia Popular or by the program distribution system. According 
to Helfer et al.10, the lack of access to medicines provided for free, especially medicines for 
CNCD, may compromise family budget and the treatment persistence, worsening  the health 
status and consequently increasing expenses with outpatient visits and hospitalizations. 
Moreover, the majority of population that uses the public health system has low income, 
and free delivery is usually the only alternative of access to medicines.
Some limitations of this study must be considered. Availability was determined using a 
specific list of medicines, with a single data collection at each place. Therefore, availability 
can be under or overestimated, being impossible to evaluate the existence of an association 
between availability and local arrangements adopted for the medicines supply. Another 
important limitation relates to municipal lists of essential medicines. We did not evaluate 
the lists adopted by each city and, consequently, we were not able to identify the existence 
of therapy options for unavailable items. In addition, we considered as available the 
medicine with at least one posologic unit in stock, but would be important information 
about the existence of enough units for provision of therapeutic schemes, according to 
the demand of services10. Another limitation concerns the study design, which is cross-
sectional and assesses availability in a determined period, and therefore does not allow 
concluding whether the lack or existence of medicines is constant or limited to that 
determined period. 
Despite its limitations, this study presents important information about the availability 
of medicines in the public sector, mentioning issues in the implementation of medicines 
and pharmaceutical services policies, as well as the need for improving management 
and reorganization of pharmaceutical services to ensure the adequate supply of essential 
medicines. Frequent shortages of items considered essential may compromise the credibility 
of the public system4 and affect health care costs. Availability of medicines for chronic 
diseases in developing countries is critical for treatment effectiveness and equity of access 
to these products24,25.
Although Brazil pioneered the adoption of a essential medicines list and of the public funding 
guaranteed by the SUS, the average availability of tracer medicines in all regions of the Country 
was lower than 80%, which is the percentage recommended by WHO. Therefore, the challenge 
of ensuring access to medicines in primary health care still remains. Low availability may 
affect treatments, raise health care costs, and impair the population quality of life. 
d Medicines provided freely by 
the Popular Pharmacy Program 
comprise the strategy Saúde 
não tem preço, which includes 
medicines for hypertension, 
diabetes, and asthma. Ministério 
da Saúde (BR), Elenco oficial dos 
medicamentos disponibilizados 
gratuitamente pelo Programa 
Aqui tem Farmácia Popular 
(updated in 01/29/2016). 
Brasília (DF); 2016 [cited 2016 
March 4]. Available from: http://
portalsaude.saude.gov.br/images 
/pdf/2016/fevereiro/02/rol-
medicamentos-SNTP-290116.pdf
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The lowest availability rates identified in small cities, associated with the low availability of 
medicines purchased by the Brazilian Ministry of Health, shows eventual deficiencies in the 
supply chain and in the management of pharmaceutical services. Similar to the Estratégia 
Saúde da Família (FHS – Family Health Strategy), both the federal and state governments, 
along with cities, must assume the responsibility of providing minimum standards of 
structure and quality to dispensing units, to increase the availability of medicines in the SUS.
The evaluation of the essential medicines’ availability must be continuous, as part of a process 
of monitoring and evaluation of the medicines and pharmaceutical services’ national policies. 
The data here presented provide support for improving public pharmaceutical services and 
constitute a baseline to evaluate the long-term impact of strategies and policies adopted in 
the Country, aiming to improve the quality of services provided, health indicators, and thus 
ensure the population’s right to health.
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